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Di-phenyl-di-(2,4-diﬂuobenzohydroxamato)tin(IV)(DPDFT), a new metal-based arylhydroxamate antitumor complex, showed
high in vivo and in vitro antitumor activity with relative low toxicity, but no data was reported regarding its pharmacokinetics and
dependent toxicity. In this paper, a rapid, sensitive, and reproducible HPLC method in vivo using Diamonsil ODS column with
a mixture of methanol and phosphoric acid in water (30:70, V/V, pH 3.0) as mobile phase was developed and validated for the
determination of DPDFT. The plasma was deproteinized with methanol that contained acetanilide as the internal standard (I.S.).
The photodiode array detector was set at a wavelength of 228nm at room temperature and a linear curve over the concentration
range 0.1∼25μg·mL−1 (r = 0.9993) was obtained. The method was used to determine the concentration-time proﬁles for DPDFT
in the plasma after single intravenous administration with doses of 5, 10, 15mg·kg−1 to rats. The pharmacokinetics parameter
calculations and modeling were carried out using the 3p97 software. The results showed that the concentration-time curves of
DPDFT in rat plasma could be ﬁtted to two-compartment model.
1.Introduction
Metals oﬀer potential advantages over the more common
organic-based drugs, including a wide range of coordination
numbers and geometries, accessible redox states, “tuneabil-
ity” of the kinetics of ligand substitution, as well as a wide
structural diversity. Medicinal inorganic chemistry is a thriv-
ing area of research [1, 2], initially fueled by the discovery of
cisplatin, a metal-based antitumor drug about 40 years ago.
Since the discovery of cisplatin and its introduction in the
clinics, metal compounds have been intensely investigated in
viewoftheirpossibleapplicationincancertherapy.Platinum
anticanceragents,suchascisplatin,havebeenhighlysuccess-
ful but there are several disadvantages associated with their
clinical use. What needs to be recognized is that there are
many other nonplatin metal-based antitumor drugs in the
periodic table with therapeutic potential. Diorganotin(IV)
complexes are potential antitumor agents mainly active
against P388 lymphocytic leukemia and other tumors [3–5].
Lately, these antitumor agents are actually being studied
widely. Among diorganotin(IV) compounds, dibutyltin(IV)
derivatives of hydroxamic acid have received more attention
due to their structural and biological importance [6–8].
Recently, we reported a series of diorganotin(IV) aryl-
hydroxamates which exhibit in vitro antitumor activities
(against a series of human tumor cell lines) which, in some
case, are identical to, or even higher than, that of cisplatin
[3, 5]. Di-phenyl-di-(2,4- diﬂuobenzohydroxamato)tin(IV)
(DPDFT, its structure was shown in Figure 1), a kind
of eﬃcient diorganotin(IV) patent compound (number:
ZL01135148 and 102826Z) with lower toxicity, is a potential
antitumor candidate for the clinical application due to its
high in vivo and in vitro activity mainly against hepatoma,
gastric cancer, nasopharyngeal carcinoma and other tumors
(data not shown here). However, its antitumor molecular
action mechanism is still unclear. In order to study the
precise action mechanism and toxicity of this metal-based
antitumor diorganotin(IV) compound, its fate should be2 Bioinorganic Chemistry and Applications
ﬁrst elucidated in vivo, including their absorption, distri-
bution, metabolism, and elimination. However, nothing is
known about the pharmacokinetic behavior of DPDFT in
body. Therefore, it is essential to establish a rapid, sensitive,
and accurate method to determine the pharmacokinetic of
organotin compound DPDFT in a body.
For medical care, practical, robust, simple, and eﬃcient
analytical methods are needed. Several methods have been
reported for the determination of organotin compounds,
including HPLC-MS [9, 10], HPLC-ICP-MS [10, 11], GC
[12], GC-MIP AED [12–14], GC-MS [15–17], GC-ICP MS
[18, 19], and so on. However, these methods have obvious
disadvantages. For examples, GC methods have complicated
pretreatments for the samples and seem to be unsuitable
for quantitative determination in rat plasma because only a
small amount of blood is normally used in pharmacokinetic
studies. HPLC-MS is superior method and should be used
whenever is possible. MS methods were used for mentioned
analysis in order to increase selectivity of detection of
DPDFT from complex matrixes. However, in this study, the
HPLC-MS method was not used because the mass spec-
trometry conditions were still not ripe for DPDFT detection,
and the high analysis cost and the expensive apparatus
required were other considerations. So far, to the best of our
knowledge, no method has been reported for determination
of the diorganotin(IV) patent compound DPDFT by HPLC
method with UV detection in the pharmacokinetic studies
in rat plasma. Therefore, in this research, we chose DPDFT
as a typical antitumor diorganotin(IV) arylhydroxamate to
develop a simple, sensitive, and speciﬁc HPLC assay for its
quantitative determination in rat plasma and to investigate
its preliminary pharmacokinetic properties.
2. Experimental
2.1. Materials and Reagents. DPDFT used in analysis was
synthesized by the same method as described in [20]. Its
purity was 99.9%. Acetanilide used as an internal standard
(I.S.) was purchased from Sigma Laboratories (St. Louis,
MO). The chromatographic solvents and reagents such as
methanol and phosphoric acid were obtained from the
National Institute for the Control of Pharmaceutical and
Biologic Products (Beijing, China). All substances were of
chromatographic grade. Deionized water was prepared using
a Milli-Q water purifying system from Millipore Corp.
(Bedford, MA).
2.2. Animal Treatment. Laboratory bred adult Wistar albino
rats (200–250g), which were supplied by the Animal Re-
search Center at Shanxi Medical University (Taiyuan, Shanxi
Province,China),werehousedat25±2◦Cinawell-ventilated
animal house under 12:12h light dark cycle. The animals
drank sterilized drinking water, and standard chow diet was
supplied ad libitum to each cage. The animal experiments
were performed in accordance with the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research and
were approved by the Animal Ethics Committee of Shanxi
Medical University.
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Figure 1: Chemical structure of DPDFT.
2.3. Instrumentation and Chromatographic Conditions.
HPLC analysis was carried out using a Waters 2695 HPLC
system (Waters Associates, Milford, MA) which consisted of
a photodiode array detector, an autosampler, and a degasser.
The apparatus was interfaced to a DELL PC compatible
computer using Empower Pro software for data acquisition.
The sensitivity was 0.2 AUFS. The autosampler was cooled
to 10◦C. The column was maintained at room temperature.
Chromatographic separation of DPDFT and the I.S. was
achieved on a Diamonsil C18 column (250mm × 4.6mm,
5μm) from Dikma Technologies (Beijing, China) protected
by a SHIMADZU LC guard column at 25◦C. The mobile
phase for HPLC analysis consisted of phosphoric acid in
water (solvent A)/methanol (solvent B) (30:70, V/V, pH
3.0) with a ﬂow rate of 0.8mL·min−1. A sample volume
of 20μL was injected. Prior to use, the mobile phase was
ﬁltered through a 0.45μm hydrophilic membrane ﬁlter.
The photodiode array detector was set at a wavelength of
228nm at room temperature. Under the chromatographic
condition mentioned above, DPDFT and the I.S. acetanilide
could be separated completely in the chromatograms
(R>1.5), and there was no endogenous interference with
the chromatographic peak of DPDFT and the I.S.acetanilide.
Besides, the retention time of acetanilide (tR = 15.67min)
was very suitable as the I.S. compared to that of DPDFT
(tR = 8.34min).
2.4. Preparation of Plasma Samples. Blood samples collected
from rat blood plasma were immediately transferred to
1.5mL heparinized microcentrifuge tubes from fossa orbi-
talis of rats, and then processed for plasma by centrifugation.
The supernatant plasma (0.2mL) was then vortex-mixed
with methanol (0.4mL) containing acetanilide (0.2mL,
50.0μg·mL−1) as internal standard (I.S.) for 30s. After
vortex-mixing, the mixture was centrifuged at 13000rpm
for 10min 4◦C to separate precipitated proteins. The super-
natant solution of methanol layer was ﬁltered through a
0.45μm membrane ﬁlter. Twenty microliters of ﬁltrate
were injected into the chromatography. The same sample
processing was also applied to the recovery and to the
precision study in plasma. All harvested samples stored at
−4◦C were brought to room temperature before use and
analyzed within one week. No signiﬁcant diﬀerences were
found between the samples stored at −4◦C and those stored
at −20◦C (data not shown).Bioinorganic Chemistry and Applications 3
2.5. Bioanalytical Method Validation
2.5.1. Preparation of Stocks, Calibration Standards, and Qual-
ity Control Samples. A stock solution of DPDFT was pre-
pared in methanol at the concentration of 100mg·mL−1 and
was further diluted in HPLC mobile phase to make working
standards. The I.S. stock solution was prepared and diluted
to 50.0μg·mL−1 working solution with HPLC mobile phase.
All the stock solutions were maintained at 4◦C until use.
The linearity of HPLC method for the determination of
DPDFT was evaluated by a calibration curve in the range
of 0.1∼25μg·mL−1. Calibration standard samples were pre-
pared by adding diﬀerent concentrations of the standards of
DPDFT and 0.2mL of the I.S. working solution to the blank
plasma. The ﬁnal concentrations of DPDFT standard sam-
ples of plasma (0.1, 0.5, 1.0, 2.5, 5.0, 10.0, and 25.0μg·mL−1,
resp.) were prepared by spiking control rat plasma with
appropriate amounts of the standard stock solution pre-
pared above. The I.S. was added to each standard sample
immediately before sample processing. For the evaluation of
the linearity of the standard calibration curve, the analyses
of DPDFT in plasma samples were performed on three
independent days using fresh preparations. Each calibration
curve consisted of a double blank sample (without internal
standard), a blank sample (with internal standard), and
seven calibrator concentrations. Each calibration curve was
constructed by plotting the analyte to internal standard
peak area ratio (y) against analyte concentrations (x). The
calibration curves were ﬁtted using a least-square linear
regression model y = ax + b. The resulting a, b parameters
were used to determine back-calculated concentrations,
which were then statistically evaluated. All calibration curves
of DPDFT were constructed before the experiments with
correlation coeﬃcient (r2)o f0 . 9 9o rb e t t e r .
2.5.2. Bioanalytical Method Validation. The speciﬁcity was
deﬁnedasnon-interferencewhenDPDFTwasbeingretained
from the endogenous plasma components, and no crossin-
terference between DPDFT and the I.S. using the proposed
extraction procedure. Six diﬀerent lots of blank (DPDFT-
free plasma) were evaluated both with and without internal
standard to assess the speciﬁcity of the method.
Qualitycontrol(QC)sampleswereusedtodeterminethe
accuracy and precision of method and were independently
prepared at low (0.8μg·mL−1), medium (4μg·mL−1), and
high (20μg·mL−1) concentrations. To evaluate the accuracy
and precision, we used at least ﬁve QC samples of three
diﬀerent concentrations of DPDFT. The intraday and inter-
day accuracies were expressed as the percentage diﬀerence
between the measured concentration and the nominal con-
centrationinratplasma.Theintradayprecisionandaccuracy
were calculated using replicate (n = 6) determinations for
each concentration of the spiked plasma sample during a
single analytical run. The interassay precision and accuracy
were calculated using replicate (n = 6) determinations
of each concentration made on three separate days. The
variability of determination was expressed as the relative
standard deviation (RSD) which should be ≤15%, covering
the range of actual experimental concentrations.
The extraction eﬃciency of DPDFT was determined
by analyzing replicate sets (n = 6) of QC samples: 0.4,
8, 20μg·mL−1 for rat plasma, representing low, medium,
and high QCs, respectively. The recoveries were calculated
by comparing the peak areas of DPDFT added into blank
samples and extracted using the protein precipitation proce-
dure, with those obtained from DPDFT spiked directly into
postprotein precipitation solvent at three QC concentration
levels.
The stability of DPDFT in rat plasma was assessed by
analyzing replicates (n = 6) of QC samples at concentrations
of 0.8, 4, 20μg·mL−1, respectively. The investigation covered
the expected conditions during all of the sample storage
and process periods, which included the stability data from
freeze/thaw cycle and long-term stability tests. The con-
centrations obtained from stability studies were compared
with the freshly prepared QC samples, and the percentage
concentration deviation was calculated. In each freeze–thaw
cycle, the samples were frozen and stored at −20◦Cf o r1 0
days, then thawed at room temperature. The stability of the
fresh plasma samples was tested after keeping the samples
at −4, −20◦C and room temperature for 72h. The stability
of deproteinized samples at 10◦C in the autosampler was
evaluated up to 24h.
To determine the limit and quantiﬁcation of detection,
we prepared the dilutions of 1, 2.5, 5, 10, 15, 20, and
30ng·mL−1 DPDFT in plasma. The results were evaluated
by analyzing each plasma sample spiked with the analyte at
a ﬁnal concentration at which the signal-to-noise ratio (S/N)
was 10 and 3.
2.5.3. Pharmacokinetic Study. To evaluate the suitability
of the assay for pharmacokinetic studies, 7.5, 15, and
30mg·kg−1 of DPDFT were intravenously administered to
rats (half males and half females, resp.). Six animals were
used in each dosage by direct injection into a lateral tail
vein,withadurationofinfusionlessthan1min.Heparinized
blood samples (0.5mL) were collected at 0, 1, 3, 5, 10, 30,
60, and 120min after injection. Eighteen rats were used
for each time point. After each sampling, the removed
volume of blood was supplemented with an equal volume
of sodium chloride. The blood samples were immediately
centrifuged and the resulting plasma was prepared according
to the procedure given for the calibrators. Pharmacokinetic
calculations were performed using the observed data. Phar-
macokinetic analysis of DPDFT concentrations in plasma
was performed using two-compartment model methods via
the 3p97 software package (Chinese Pharmacology Society).
A l lv a l u e so b t a i n e dw e r ee x p r e s s e di nm e a n± standard
deviation.
3. Results and Discussion
A deproteinized method to detect DPDFT, an typical antitu-
mor diorganotin(IV) compound in plasma, was ﬁrst devel-
oped in this paper. Diverse proportional solvents (methanol
and acidiﬁed water) were selected in the deproteinizing
process. The plasma deproteinized with double volume of4 Bioinorganic Chemistry and Applications
methanol could produce the minimal dilution, optimum
peak shape, and an increase of detector sensitivity along with
the satisfactory recovery.
3.1. Wavelength Selection Results. The Waters 2695 HPLC–
DAD measurement was performed under the chromato-
graphic condition mentioned above. Chromatographic sep-
aration of DPDFT was achieved on a Diamonsil C18 column
(250mm × 4.6mm, 5μm) protected by a SHIMADZU
guard column at 25◦C. The mobile phase for HPLC analysis
consisted of phosphoric acid in water (solvent A)/methanol
(solvent B) (30:70, V/V, pH 3.0) with a ﬂow rate of
0.8mL·min−1. A sample volume of 20μL was injected. The
D A Dw a v e l e n g t hr a n g ew a ss e to n1 9 0 ∼400nm with a slid
width of 1nm and a response time of 2.0s at room tem-
perature. As shown in Figures 2(a), 2(b),a n d2(c), the
peaks were detected with good baseline separation. Peak
identiﬁcation was conﬁrmed by comparison of UV spec-
tra. The maximum absorption wavelength of DPDFT was
228nm, and there was no endogenous interference with the
chromatographic peak of DPDFT.
3.2. Validation Data of Bioanalytical Method. The method
was validated using the criteria described above. The data
were found to be linear over a concentration range of
0.1∼25μg·mL−1 in blood samples. The regression equation
was y = 32.001x +0 .31, with the correlation coeﬃcient r =
0.9993 (n = 7), where y represented the peak-area ratio of
DPDFT to the I.S. in rat plasma and x was the concentration
ofDPDFT.Thelimitofquantitation(LOQ)was10ng,which
can be determined with a relative error (RE) and precision
(RSD) of <15% at a signal to-noise ratio of 10. The limits of
detection(LOD)were3.5ng,basedonasignal-to-noiseratio
of 3.
Under the chromatographic condition, the number of
theoretical plates was 5000. The degree of interference by
endogenous plasma with DPDFT and the I.S. was assessed
by inspection of chromatograms derived from a processed
blank plasma sample. The results show that there were no
endogenousinterferingpeakswiththeI.S.andDPDFTinthe
rat plasma. Typical chromatograms of blank plasma, blank
plasma spiked with DPDFT QC sample (3μg·mL−1) and the
I.S., and a rat plasma sample after dosing with 15mg·kg−1
DPDFT are presented (Figure 3). DPDFT and the I.S. were
eluted at 15.67 and 8.34min, respectively. The total run time
was less than 30min. A good separation of the I.S. and
DPDFT was obtained under the speciﬁed chromatographic
conditions.
The recoveries of the assay were assessed by comparing
the peak-area ratios (analyte/the I.S.) obtained from spiked
plasma samples of three DPDFT standard concentrations
(0.4,8,20mg/mL)withthepeak-arearatios(analyte/theI.S.)
for the samples containing the equivalent analyte and the I.S.
which were directly dissolved in methanol. The recoveries
were approximately 90.0–97.0% in the rat plasma, as shown
in Table 1, the mean extraction recovery and the coeﬃcient
of variation RSD of DPDFT at three various concentrations
Table 1: Recoveries of the assay for determining DPDFT in rat
plasma (n = 6).
Spiked concentration
(μg/mL) Recovery (%, mean ± SD) RSD (%)
0.8 90.8 ±7.07 . 7
49 5 .7 ±12.9 13.5
20 96.2 ±10.8 11.3
from the rat plasma were 94.2%± 10.3% and 10.9% (n =
18), respectively.
The precision and accuracy of this method were evalu-
ated by assaying each low, middle, and high concentration
QC sample. The reproducibility of the method was assessed
by examining both intraday and interday variance. Accuracy
(%) = [(Cobs − Cnom)/Cnom] × 100. The precision
(%RSD) was calculated from the observed concentrations
as follows: RSD = [standard deviation (SD)/Cobs] ×100. As
shown in Table 2, the data showed that the intraday and
interday precisions (% RSD) of the three QC samples in rat
plasma were <15%. The RSD values of the intraday and the
interday for rat plasma samples ranged from 3.8%∼9.0%
and 4.0% ∼9.0%, respectively. These validations demon-
strated the reliability of the assay.
Stability of DPDFT during storage and processing was
checked using quality control samples. The DPDFT and
I.S. stock solutions were stable for at least 2 months when
stored at 4◦C. The deviation of the mean test responses was
within ±10% of appropriate controls in all stability tests
of DPDFT in rat plasma. After three freeze-thaw cycles,
the concentration changes of DPDFT were less than 7%.
The analyte was stable in the matrices at 4, −20◦Ca n d
room temperature for 72h without signiﬁcant degradation
(<8%). The run-time stability study showed that DPDFT in
deproteinized rat plasma was stable at 10◦Cf o ru pt o2 4h
(<6%). These results suggested that the rat plasma samples
containing DPDFT can be handled under normal laboratory
conditions without signiﬁcant loss of the compound. All
stability results are summarized in Table 3.
3.3. Pharmacokinetic Applicability. The developed RP-HPLC
analytical method has been successfully used for the phar-
macokinetic study after a single intravenous administration
of DPDFT within 120min. The mean plasma concentration-
time curves of DPDFT after administration of 7.5, 15, and
30mg·kg−1 in rats are shown in Figure 4, the concentration-
time data conformed to a two-compartment model and
the major mean pharmacokinetic parameters (mean ± SD)
are summarized in Table 4. The RP-HPLC method satisﬁed
the requirement of this study and demonstrated its general
suitability for pharmacokinetics studies of DPDFT in rats.
3.4. The Pharmacokinetics Features of DPDFT in Rat Plasma.
HPLC analysis for amphoteric, polar substances with low
wavelength ultraviolet absorption is always associated with
some diﬃculties, especially when high sensitivity is required.
The results showed that this classic liquid extraction HPLCBioinorganic Chemistry and Applications 5
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Figure 2: HPLC-DAD proﬁles of DPDFT in plasma sample. (a) Blank plasma; (b) DPDFT (2μg·mL−1) standard; (c) blood sample
containing DPDFT (2.4μg·mL−1) collected at 3min after administration of DPDFT (15mg·kg−1, i.v.).
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Figure 3: Chromatograms of DPDFT in plasma sample. Separation was performed using Waters 2695 HPLC system. The mobile phase
consisted of phosphoric acid in water (solvent A)/methanol (solvent B) (30:70, V/V, pH 3.0) using Diamonsil C18 column at 25◦Cw i t ha
ﬂow rate of 0.8mL·min−1. (a) Blank plasma; (b) blank plasma spiked with DPDFT (3μg·mL−1) and the I.S. (8μg·mL−1); (c) blood sample
containing DPDFT (2.4μg·mL−1) collected at 3min after administration of DPDFT (15mg·kg−1, i.v.).
with UV detecting method was sensitive (the limit of
detection was 3.5ng) enough for pharmacokinetics studies
of DPDFT in rats and did not require any forms of analyte
derivatization or special columns or instruments. The most
important factor for achievement of high sensitivity was
the clean baseline owing to appropriate sample preparation
on the chromatograms. Thus, a high signal/noise ratio was
achieved, which constituted the base for the high sensitivity.
The second factor was the high recovery of DPDFT from
plasma during the extraction process. Methanol was used
not only for deproteination, but also as extractive solvent
for assay. So, the high recoveries of DFDPT (90.8, 95.7, and
96.2% for three determinations, resp.) were obtained. Dur-
ing the process of method development, it was discovered
that DPDFT spiked with aqueous I.S. showed a symmetric
single peak in the chromatograms at a pH around 3.0.
With high sensitivity, small sample requirement, and simple
sample treatment procedures, this method was successfully
applied to the analysis of rat plasma samples and the
pharmacokinetic study of DPDFT in rat.
The mean pharmacokinetic parameters (mean ± SD)
are summarized in Table 4. There were no signiﬁcant diﬀer-
ences in all pharmacokinetic parameters between male and
female rats at dose of 7.5, 15, and 30mg·kg−1. The results
showed that there was signiﬁcant diﬀerence for AUC(0–t),
they were calculated to be 7.56, 37.15, 81.25mg·kg−1·min−1
at doses of 7.5, 15, and 30mg·kg−1,r e s p e c t i v e l y ,a n df o r
the value of Vd after three dosages, 2.13, 1.13, 0.62L·kg−1,
respectively. These results suggested that the pharmacoki-
netics of the complex is a nonlinear process from 7.5 to
30mg/kg. Otherwise, the distribution half-life t1/2a (1.04,
1.01, 1.12min, resp.) and elimination half-life t1/2β (17.68,6 Bioinorganic Chemistry and Applications
Table 2: Intra- and interday precision and accuracy for DPDFT in rat plasma (n = 6).
Matrix Nominal concentration (μg·mL−1) Observed concentration (μg·mL−1) ± SD Precision (%RSD) Accuracy (%)
Intra-day
0.8 0.73 ±0.05 6.8 −8.75
43 .73 ±0.14 3.8 −6.75
20 19.21 ±1.02 5.3 −3.95
Inter-day
0.8 0.69 ±0.06 8.7 −13.75
43 .80 ±0.15 4.0 −5.00
20 19.02 ±1.11 5.9 −4.90
Notes: accuracy (%) = [(Cobs − Cnom)/Cnom] × 100, RSD = [standard deviation (SD)/Cobs] × 100.
Table 3: Stability results of DPDFT at diﬀerent conditions in rat plasma (n = 6).
Storage period and storage condition Nominal concentration
(μg·mL−1)
Observed concentration
(μg·mL−1) ± SD Accuracy (%) RSD (%)
Concentration of fresh preparation
0.8 0.85 ±0.07 6.25 8.2
43 .91 ±0.12 −2.25 3.1
20 21.06 ±1.33 5.30 6.3
Three freeze and thaw cycles
0.8 0.76 ±0.05 −5.00 6.6
43 .79 ±0.13 −5.25 3.5
20 18.97 ±1.17 −5.15 6.2
Stability for 72h at 4◦C
0.8 0.87 ±0.04 8.75 4.6
43 .70 ±0.16 −7.50 4.3
20 21.14 ±1.27 5.70 6.0
Stability for 72h at −20◦C
0.8 0.74 ±0.05 −7.50 6.8
44 .22 ±0.12 5.50 2.9
20 19.13 ±1.53 −4.35 7.9
Stability for 72h at room temperature
0.8 0.78 ±0.05 −2.50 6.4
43 .87 ±0.19 −3.25 4.9
20 19.46 ±1.19 −2.75 6.1
Autosampler stability for 24h at 10◦C
0.8 0.83 ±0.04 3.75 4.8
43 .83 ±0.18 −4.25 4.7
20 19.19 ±1.08 −4.05 5.6
Notes: accuracy (%) = [(Cobs − Cnom)/Cnom] × 100, RSD = [standard deviation (SD)/Cobs] × 100.
Table 4: Mean pharmacokinetic parameters in rats after intravenous administration of 7.5, 15, and 30mg·kg−1 of DPDFT (mean ± SD,
n = 6).
Parameter (unit)
Dosage/mgkg−1
7.5 (low) 15 (middle) 30 (high)
A/min−1 2.21 ± 0.03 7.94 ±3.12 22.36 ±8.12
B/mg·kg−1 0.15 ± 0.04 0.92 ±0.04 1.85 ±0.44
β/min−1 0.04 ±0.003 0.04 ±0.003 0.04 ±0.003
Vd/L·kg−1 2.13 ± 0.07 1.13 ±0.08 0.62 ±0.08
t1/2a/min 1.04 ± 0.01 1.01 ±0.01 1.12 ±0.1
t1/2β/min 17.68 ±2.61 9 .38 ±3.61 6 .81 ±3.6
K21/min−1 0.08 ±0.004 0.11 ±0.01 0.09 ±0.01
K10/min−1 0.32 ± 0.05 0.24 ±0.08 0.30 ±0.18
K12/min−1 0.26 ± 0.04 0.38 ±0.01 0.28 ±0.11
AUC/mg·kg−1min−1 7.56 ± 1.02 37.15 ±3.06 81.25 ±15.3
CL(s)/mg·mL−1,m gk g −1 0.66 ± 0.05 0.27 ±0.02 0.018 ±0.02Bioinorganic Chemistry and Applications 7
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Figure 4: Mean plasma concentration-time proﬁles of DPDFT in
rats after intravenous administration of 7.5, 15, and 30mg·kg−1.
Each point represents the mean concentration of six rats.
19.38, 16.81min, resp.) have no signiﬁcant diﬀerence when
the administration dosage of DPDFT was increased from
7.5 to 30mg/kg, indicating that DPDFT distributed and
eliminated very quickly.
4. Conclusions
In this paper, a simple, economical, sensitive, and speciﬁc
methodforthedeterminationofDPDFT,atypicalantitumor
diorganotin(IV) compound in rat plasma, was ﬁrst reported.
The assay was validated for linearity, speciﬁcity, accuracy,
precision, recovery, and stability, and good results were
obtained.Theresultsofpreliminarypharmacokineticstudies
indicated that DPDFT showed nonlinear pharmacokinetics
in the studied dose ranges in rats and the concentration-
time curves of DPDFT in rat plasma could be ﬁtted to
two-compartment model. These results hinted that DPDFT
might accumulate in certain organs, thus produce the
toxicity or could be quickly metabolized in the plasma into
activeconstituentforantitumor.Inordertostudytheprecise
toxicity mechanism of this metal-based antitumor diorgan-
otin(IV) compounds, we should further elucidate their in
vivo absorption, distribution, metabolism, and elimination.
Meanwhile, based on the structure of DPDFT as a lead com-
pound, structure reconstitution and optimization should be
carried out to explore the better antitumor diorganotin(IV)
compounds with higher activity, relative lower toxicity, and
good pharmacokinetics features in the future.
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